Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and ...
The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
The Canadian Press on MSN8h
Fentanyl has killed thousands. Here are some facts about the powerful opioidFentanyl has emerged as the primary cause of illicit drug deaths in Canada and the United States, and its trafficking has ...
Federal lawmakers are trying once again to push for a study on the “overmedication” of veterans by Department of Veterans ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
Learn more about whether Alkermes plc or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback